PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29468921-2	2019	The metabolism of the prostacyclin receptor agonist selexipag (NS-304; ACT-293987) and its active metabolite MRE-269 (ACT-333679) has been investigated in liver microsomes and hepatocytes of rats, dogs, and monkeys.	selexipag	52-61	prostaglandin I2 receptor	Rattus norvegicus	22-43	
20660124-0	2010	Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function.	selexipag	0-9	prostaglandin I2 receptor	Rattus norvegicus	23-44	
20660124-1	2010	Selexipag [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide] is an orally available prostacyclin (PGI(2)) receptor (IP receptor) agonist that is chemically distinct from PGI(2) and is in clinical development for the treatment of pulmonary arterial hypertension.	selexipag	0-9	prostaglandin I2 receptor	Rattus norvegicus	134-150	
20660124-1	2010	Selexipag [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide] is an orally available prostacyclin (PGI(2)) receptor (IP receptor) agonist that is chemically distinct from PGI(2) and is in clinical development for the treatment of pulmonary arterial hypertension.	selexipag	11-95	prostaglandin I2 receptor	Rattus norvegicus	134-150	
33057388-0	2020	The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.	selexipag	36-45	prostaglandin I2 receptor	Rattus norvegicus	14-27	
33057388-4	2020	Selexipag is a recently approved, orally available and selective prostacyclin receptor agonist with a non-prostanoid structure.	selexipag	0-9	prostaglandin I2 receptor	Rattus norvegicus	65-86	
33057388-9	2020	These effects were probably based on the potent prostacyclin receptor agonistic effect of selexipag on pulmonary vessels.	selexipag	90-99	prostaglandin I2 receptor	Rattus norvegicus	48-69	
17545310-3	2007	NS-304 is an orally available and potent agonist for the PGI(2) receptor (IP receptor).	selexipag	0-6	prostaglandin I2 receptor	Rattus norvegicus	57-72	
29588339-0	2018	Selective Prostacyclin Receptor Agonist Selexipag, in Contrast to Prostacyclin Analogs, Does Not Evoke Paradoxical Vasoconstriction of the Rat Femoral Artery.	selexipag	40-49	prostaglandin I2 receptor	Rattus norvegicus	10-31	
29588339-1	2018	Selexipag [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide] is a selective nonprostanoid prostacyclin (PGI2) receptor (IP receptor) agonist that is approved for the treatment of pulmonary arterial hypertension (PAH).	selexipag	0-9	prostaglandin I2 receptor	Rattus norvegicus	140-154	
29588339-1	2018	Selexipag [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide] is a selective nonprostanoid prostacyclin (PGI2) receptor (IP receptor) agonist that is approved for the treatment of pulmonary arterial hypertension (PAH).	selexipag	11-95	prostaglandin I2 receptor	Rattus norvegicus	140-154	
27919660-1	2017	Selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N- (methylsulfonyl)acetamide]) is a novel, orally available non-prostanoid prostacyclin receptor (IP receptor) agonist that has recently been approved for the treatment of pulmonary arterial hypertension (PAH).	selexipag	0-9	prostaglandin I2 receptor	Rattus norvegicus	152-173	
27919660-1	2017	Selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N- (methylsulfonyl)acetamide]) is a novel, orally available non-prostanoid prostacyclin receptor (IP receptor) agonist that has recently been approved for the treatment of pulmonary arterial hypertension (PAH).	selexipag	20-105	prostaglandin I2 receptor	Rattus norvegicus	152-173	
28277164-0	2018	Pharmacokinetics of the selective prostacyclin receptor agonist selexipag in rats, dogs and monkeys.	selexipag	64-73	prostaglandin I2 receptor	Rattus norvegicus	34-55	
28277164-2	2018	This study examined the pharmacokinetics, distribution, metabolism and excretion of the selective prostacyclin receptor agonist selexipag (NS-304; ACT-293987) and its active metabolite MRE-269 (ACT-33679).	selexipag	128-137	prostaglandin I2 receptor	Rattus norvegicus	98-119	
22918043-1	2012	{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (ACT-333679) is the main metabolite of the selective prostacyclin (PGI(2)) receptor (IP receptor) agonist selexipag.	selexipag	172-181	prostaglandin I2 receptor	Rattus norvegicus	133-149